Idiopathic intracranial hypertension

Sonorous NV Uses New Device to Treat Patients with Symptomatic Cerebral Venous Diseases

Retrieved on: 
Friday, December 16, 2022
Idiopathic intracranial hypertension, Michael (archangel), Standard of care, Physician, Innovation, Tinnitus, Patient, Papilledema, Inc., FDA, Hospital, IIH, St. Michael's Hospital (Toronto), Medical device, EU

LAKE FOREST, Calif., Dec. 16, 2022 /PRNewswire/ -- Sonorous NV, Inc. Chairman, Dave Ferrera, announced treatment of the first patients inNorth Americawith the BossStentdevice designed to treat patients with symptomatic cerebral venous diseases.

Key Points: 
  • LAKE FOREST, Calif., Dec. 16, 2022 /PRNewswire/ -- Sonorous NV, Inc. Chairman, Dave Ferrera, announced treatment of the first patients inNorth Americawith the BossStentdevice designed to treat patients with symptomatic cerebral venous diseases.
  • The single-use, disposable device is an endoluminal device that is placed into a cerebral venous sinus stenosis to normalize blood flow and pressure gradients causing pulsatile tinnitus and/or IIH (idiopathic intracranial hypertension), etc.
  • It offers a breakthrough solution for patients with symptomatic cerebral venous diseases associated with venous sinus stenosis who require interventional therapy.
  • Added Ferrera, "We are confident that use of the BossStentdevice will provide an on-label solution for symptomatic cerebral venous diseases leading to papilledema, pulsatile tinnitus and IIH.

Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin

Retrieved on: 
Monday, November 28, 2022
Precocious puberty, Idiopathic intracranial hypertension, Use, Multimedia, IND, Therapy, Particle size, Patient, IIH, SR, MHRA, Endometriosis, Prostate cancer, Composition, KOSDAQ, Breast cancer, FDA, Pharmaceutical industry, Leuprorelin, Takeda

Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin.

Key Points: 
  • Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin.
  • PT105 represents Korea's first commercialized generic drug of Leuplin, applied with SmartDepot technology.
  • "Compared to Takeda's Leuplin, PT105 has reduced particle size and smaller needle gauge, which will improve patients' convenience," said an official of Peptron.
  • "After the launch of PT105 in the domestic market, we will enter the global market with potential partners based on established bioequivalence and international standards."

Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin

Retrieved on: 
Monday, November 28, 2022
Precocious puberty, Idiopathic intracranial hypertension, Use, IND, Therapy, Particle size, Patient, IIH, SR, MHRA, Endometriosis, Prostate cancer, Composition, KOSDAQ, Breast cancer, FDA, Pharmaceutical industry, Leuprorelin, Takeda

Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin.

Key Points: 
  • Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin.
  • PT105 represents Korea's first commercialized generic drug of Leuplin, applied with SmartDepot technology.
  • "Compared to Takeda's Leuplin, PT105 has reduced particle size and smaller needle gauge, which will improve patients' convenience," said an official of Peptron.
  • "After the launch of PT105 in the domestic market, we will enter the global market with potential partners based on established bioequivalence and international standards."

Imperative Care Announces Positive Real-World Data Showing that the Zoom Stroke Solution Achieved Superior Procedure Outcomes with Lower Cost in Ischemic Stroke Patients

Retrieved on: 
Tuesday, July 26, 2022
Health, Medical Devices, Surgery, Health Technology, Clinical Trials, Research, Science, Pathology, Brain, Time, MCA, Idiopathic intracranial hypertension, Reperfusion, Solution, Zoom, Ohio State University, Thrombectomy, Safety, Moyamoya disease, LDP, Catheter, Neuroradiology, Society, COO, Technology, Patient, Stroke, Association, Ohio State University Wexner Medical Center, Contraindication, University of Arizona, ICA, Pharmaceutical industry, Medical imaging, Medical device, Northern Arizona University

today announced that new data from studies evaluating the utility of the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting in Toronto.

Key Points: 
  • today announced that new data from studies evaluating the utility of the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting in Toronto.
  • At Imperative Care, we know that clinical data are foundational to validating medical technologies and improving patient outcomes, said Daniel Davis, president and COO of Imperative Care.
  • The Zoom Stroke Solution is the complete stroke system from access through reperfusion for fast and effective clot removal for patients with acute ischemic stroke.
  • Imperative Care and Truvic are based in Campbell, Calif. https://imperativecare.com
    + Dr. Milburn is a paid consultant for Imperative Care.

Imperative Care Announces Poster Presentations on the Zoom Stroke Solution at the Society of NeuroInterventional Surgery 19th Annual Meeting

Retrieved on: 
Monday, July 18, 2022
Research, Medical Devices, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Stroke, LDP, Neuroradiology, Solution, Reperfusion, Technology, Oral, Zoom, Contraindication, Idiopathic disease, Moyamoya disease, Society, Idiopathic intracranial hypertension, Treatment, Pharmaceutical industry, Telescopic sight, Patient

today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting taking place July 25-29 in Toronto.

Key Points: 
  • today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting taking place July 25-29 in Toronto.
  • Poster presentations of the Zoom Stroke Solution at SNIS include:
    *All oral posters will be presented on Monday, July 25 between 4:15-5:45 p.m. E.T.
  • The system includes the Zoom 88 Large Distal Platform for neurovascular access, four vessel-matched Zoom Aspiration Catheters, the Zoom Pump, the Zoom POD and other accessories.
  • Imperative Care is a medical technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke.

MCRA Expands Neurology Division into Neurointerventional Market

Retrieved on: 
Wednesday, September 22, 2021
Elective surgery, Stroke, Contract research organization, Quality assurance, Dural arteriovenous fistula, VB, FDA, Patient, Engineering, Intracranial aneurysm, Neurosurgery, IVD, Hydrocephalus, Food and Drug Administration, General surgery, Computer security, LLC, Neurology, MCRA, Idiopathic intracranial hypertension, Trial of the century, Journal of NeuroInterventional Surgery, DC, Boston Scientific, Technology, Research, Epidural hematoma, CRO, Robotics, Spine, Industry, Google Images, Medical device

Herrmann also had significant interactions onapplications for the clinical use ofdrug and biologic baseddevice combination products during his time with the agency.

Key Points: 
  • Herrmann also had significant interactions onapplications for the clinical use ofdrug and biologic baseddevice combination products during his time with the agency.
  • Dr. Herrmann said "I am very excited to join the highly distinguished team at MCRA and expand their regulatory expertise in the area of neurointerventional devices.
  • About MCRA, LLC:MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.
  • MCRA has offices in Washington, DC, Hartford, CT, and New York, NY, and serves more than 700 clients globally.

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Rising Incidences of Idiopathic Intracranial Hypertension to Boost Growth | Technavio

Retrieved on: 
Thursday, February 6, 2020
Pharmaceutical, Health, Mental health, Companies, Life sciences, Articles, RTT, CAC 40, Sanofi, Pfizer, Teva Pharmaceutical Industries, AbbVie Inc., Pharmaceutical industry, Mylan, Idiopathic intracranial hypertension

Our idiopathic intracranial hypertension therapeutics market report covers the following areas:

Key Points: 
  • Our idiopathic intracranial hypertension therapeutics market report covers the following areas:
    This study identifies increasing number of awareness campaigns as one of the prime reasons driving the idiopathic intracranial hypertension therapeutics market growth during the next few years.
  • Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Vendor Analysis
    We provide a detailed analysis of around 25 vendors operating in the idiopathic intracranial hypertension therapeutics market, including some of the vendors such as AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the idiopathic intracranial hypertension therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Key Highlights
    Technavio is a leading global technology research and advisory company.